Document is current
Any future updates will be listed below
-
Authors
Sator, Paul
Loewe, Robert
Zamani, Omid
Holzer, Gregor
Wolf, Peter
Mlynek, Alexander
Berger, Thomas
Richter, Leo
Schuller, Elisabeth https://orcid.org/0000-0003-4979-2945
- License Information
-
More Information
Article History
Received: 19 September 2018
Revised: 1 August 2019
Accepted: 5 September 2019
First Online: 7 October 2019
Conflict of interest
: P. Sator received research grants, honoraria for taking part in advisory boards or presenting at meetings and/or participated in clinical trials Abbott, AbbVie, Actelion, ALK, Almirall, Amgen, Celgene, Galderma, Gilead, Janssen, Lilly, Maruho, MSD, Novartis, Leo Pharma, Pfizer and UCBR. R. Loewe has been an advisor and/or received speaker honoraria/grants and/or participated in clinical trials for Almirall Hermal, Novartis, BMS and Merck. G. Holzer received research grants, honoraria for taking part in advisory boards or presenting at meetings and/or participated in clinical trials for Almirall, Eli Lilly, Janssen, Leo Pharma, Merck Sharp & Dohme and Pfizer. P. Wolf received research grants, honoraria for taking part in advisory boards or presenting at meetings and/or travel support from AbbVie, Almirall, Eli Lilly, Janssen, Leo Pharma, Merck Sharp & Dohme and Pfizer. A. Mlynek has been an advisor and/or received speaker honoraria and/or honoraria for taking part in advisory boards and/or participated in clinical trials for Almirall Hermal, Novartis, AbbVie, Eli Lilly, Janssen and Pfizer. O. Zamani and T.Berger have no conflict of interest to declare. L. Richter received honoraria for taking part in advisory boards or presenting at meetings for AbbVie, Almirall, BMS, Celgene, Janssen, GSK, LEO, Lilly, MSD, Novartis, Pfizer, Roche, UCB. E. Schuller is an employee of Almirall GmbH.
